Belite Bio, Inc is a clinical-stage drug development company dedicated to creating novel therapeutics for degenerative retinal diseases with significant unmet medical needs, such as Stargardt disease and geographic atrophy in advanced dry age-related macular degeneration. The company is also involved in developing treatments for specific metabolic diseases, leveraging its expertise in RBP4 inhibition as a mechanism of action.